Proof of viability studies

The final selected c4c non-industry Proof of Viability studies includes three studies covering different diseases and age groups.

 

TREOCAPA

Paracetamol in Premature Babies

This study will assess the effectiveness of paracetamol on the closure of the ductus arteriosus and the increase in surviving without severe morbidity in extremely premature infants. The study aims to recruit around 800 babies in 17 European countries.

In Switzerland we have study sites in Zurich, Geneva and Lausanne.

cASPerCF

Prospective validation & clinical evaluation of a new posaconazole dosing regimen for children & adolescents with cystic fibrosis and Aspergillus

The study will assess the dose of posaconazole in children and young people with Cystic Fibrosis and Aspergillus infection and aims to recruit 135 children as part of the study.

In Switzerland, the University children's hospital Zurich participates in this study.

KD-CAAP

Kawasaki Disease Coronary Artery Aneurysm Prevention trial

This study will assess the effectiveness of adding steroids to standard treatment in children with Kawasaki Disease, and aims to recruit 262 children as part of the study.

We are pleased to inform you that the Kawasaki Disease Coronary Artery Aneurysm Prevention trial (KD-CAAP) study has opened its first site at Great Ormond Street Hospital, London. This is the first of the three non-industry proof of viability studies to open a site for recruitment.  

Please find attached the press release and link to the published press release on the c4c website.

In Switzerland, so far we do not have a participating study site. This could still change.

MEMBERS